A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
Purpose
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
Condition
- Focal Epilepsy
Eligibility
- Eligible Ages
- Between 18 Years and 75 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Male and Female participants 18 to 75 years of age at time of consent. 2. Diagnosis of Focal Onset Epilepsy at least 1 year prior to screening visit defined by 2017 International League Against Epilepsy (ILAE) Classification and based on requirements of Epilepsy Adjudication criteria. a. Focal seizures i. Focal aware seizures with clinically observable signs and/or symptoms ii. Focal impaired awareness seizures iii. Focal to bilateral tonic-clonic seizures 3. Subject meets the 2009 ILAE definition of drug resistant epilepsy, failure of adequate trials of two tolerated and appropriately chosen and used anti-seizure medication (ASM) schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom. 4. Ability to keep accurate seizure diaries 5. Current treatment with at least 1 and up to 3 ASMs and 4 epilepsy treatments in total
Exclusion Criteria
- History of status epilepticus (convulsive status epilepticus for > 5 minutes or focal status epilepticus with impaired consciousness for > 10 minutes) within the last 6 months prior to screening visit that is not consistent with the subject's habitual seizure. 2. History of repetitive/cluster seizures (where individual seizures cannot be counted) within the last 6 months prior to screening visit and during observation phase. 3. Resection neurosurgery for seizures <4 months prior to the screening visit. 4. Radiosurgery performed <2 years prior to the screening visit. 5. Subjects with only focal aware nonmotor seizures which involve subjective sensory or psychic phenomena only, without impairment of consciousness or awareness (formally called simple partial seizures), with or without ictal EEG correlation with clinical symptoms. 6. Any condition that would interfere with the subject's ability to comply with study instructions, place the subject at unacceptable risk, and/or confound the interpretation of safety or efficacy data from the study, as judged by the Investigator
Study Design
- Phase
- Phase 2/Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Experimental BHV-7000 25 mg |
|
|
Experimental BHV-7000 50 mg |
|
|
Placebo Comparator Placebo |
|
Recruiting Locations
Phoenix, Arizona 85013
Tucson, Arizona 85718
Little Rock, Arkansas 72205
Rogers, Arkansas 72758
Tyler Karnes
479-927-3000
La Jolla, California 92041
Los Angeles, California 90095
Palo Alto, California 94304
Pasadena, California 91105
Aurora, Colorado 80045
Boca Raton, Florida 33486
Bradenton, Florida 34209
Jacksonville, Florida 32209
Miami, Florida 33136
Miami, Florida 33179
Orlando, Florida 32804
Port Charlotte, Florida 33952
Tampa, Florida 33615
Weston, Florida 33331
Honolulu, Hawaii 96817
Boise, Idaho 83702
Chicago, Illinois 60611
Elgin, Illinois 60123
Lexington, Kentucky 40504
Roseville, Minnesota 55113
Saint Louis, Missouri 63110
Livingston, New Jersey 07039
Amherst, New York 14226
New York, New York 10021
Stony Brook, New York 11794
Woodmere, New York 11598
Mooresville, North Carolina 28117
Winston-Salem, North Carolina 27157
Canton, Ohio 44718
Cincinnati, Ohio 45267
Philadelphia, Pennsylvania 19104
Philadelphia, Pennsylvania 19107
Nashville, Tennessee 37232
Dallas, Texas 75243
Houston, Texas 77030
San Antonio, Texas 78229
San Antonio, Texas 78249
Salt Lake City, Utah 84132
Charlottesville, Virginia 22903
Richmond, Virginia 23235
Roanoke, Virginia 24011
More Details
- NCT ID
- NCT06132893
- Status
- Recruiting
- Sponsor
- Biohaven Therapeutics Ltd.